MedTrace Logo

A Phase 1 Study of ADI-001 in B Cell Malignancies

NCT04735471 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2025-06-18

No results posted yet for this study

Summary

This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of this study is to evaluate the safety and efficacy of ADI-001 in patients with B cell malignancies.

Conditions

Interventions

GENETIC

ADI-001

Anti-CD20 CAR-T

DRUG

Fludarabine

Chemotherapy for Lymphodepletion

DRUG

Cyclophosphamide

Chemotherapy for Lymphodepletion

Sponsors & Collaborators

  • Adicet Therapeutics

    lead INDUSTRY

Principal Investigators

  • Adicet Medical Director · Adicet Bio

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-04
Primary Completion
2025-02-03
Completion
2025-02-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04735471 on ClinicalTrials.gov